myTomorrows

Netherlands-based myTomorrows is a clinical trial technology provider that helps physicians identify and enroll their patients in experimental treatments. The company does this through its platform, which helps streamline the search for potential treatments using a patient's information and the physician’s input. The company claims its solution can cut down the time taken to identify potential treatments by 90%.

The company operates on a B2B model, working with healthcare providers and pharmaceutical companies to help identify treatments for patients and list potential treatments, respectively.

In April 2023, the company launched a beta offering of its new AI-based treatment access identifying tool, “TrailSearch AI.” The program helps physicians identify possible treatments that have yet to gain approval based on patient health profiles. The platform uses large language models (LLM) to sift through global databases to identify potential treatment candidates around the world.

In June 2024, the company appointed Marshall Van Beurden as the new chief technology officer (CTO).

Key partnerships and customers

myTomorrows has historically partnered with several pharmaceutical companies in order to provide patients with access to new therapeutics. These include partnerships with entities such as AiCuris, Omeros Corporation, Precision-Panc, and Basilea Pharmaceutica.

As of June 2024, the company’s platform was available in more than 50 countries and had helped over 11,000 patients access treatment. The company also noted that it had a community of 2,000+ healthcare professionals, and its platform had been used by 50+ biopharma partners.

More recently, the company entered partnerships with the following;

In September 2020, the company partnered with Notable, a precision medicine company, to provide myTomorrows’ users access to treatments developed by physicians and researchers collaborating with Notable. Patients have access to these treatments via myTomorrows’ pre-approval treatment option while myTomorrow will facilitate patient referrals to physicians and researchers working with Notable.

In October 2020, the company partnered with Atara Biotherapeutics, a biopharmaceutical developer, to develop an Expanded Access Program to Atara’s investigational drug candidate, “tabelecleucel” for Epstein-Barr virus (EBV)-driven diseases.

In February 2020, the company partnered with My Personal Therapeutics, a biotechnology company developing cancer-related treatments, to create awareness and further access to new therapeutic options for patients with colorectal cancer.

Funding and financials

In January 2017, the company raised EUR 10 million (USD 10.7 million) in a venture funding round co-led by EQT Ventures and Octopus Ventures, along with participation from other venture capital firms. The raised funds were set aside to invest in the company’s technology and hire additional staff.